Evidence map›Paper›PMID 30423998›Full record

ArticleInternational journal of environmental research and public health2018

Transitions in Tobacco Product Use by U.S. Adults between 2013⁻2014 and 2014⁻2015: Findings from the PATH Study Wave 1 and Wave 2.

Karin A Kasza, Nicolette Borek, Kevin P Conway, Maciej L Goniewicz, Cassandra A Stanton, Eva Sharma, Geoffrey T Fong, David B Abrams, Blair Coleman, Liane M Schneller and 15 more

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Potential Impact of Cessation Interventions at the Point of Lung Cancer Screening on Lung Cancer and Overall Mortality in the United States.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Karin A KaszaDepartment of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. karin.kasza@roswellpark.org.
Nicolette BorekOffice of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA. Nicolette.Borek@fda.hhs.gov.
Kevin P ConwayNational Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA. kconway@rti.org.
Maciej L GoniewiczDepartment of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Maciej.Goniewicz@RoswellPark.org.
Cassandra A StantonWestat, Rockville, MD 20850, USA. CassandraStanton@westat.com.
Eva SharmaWestat, Rockville, MD 20850, USA. EvaSharma@westat.com.
Geoffrey T FongSchool of Public Health and Health Systems, University of Waterloo, Waterloo, ON N2L 3G1, Canada. geoffrey.fong@uwaterloo.ca.
David B AbramsThe Schroeder Institute for Tobacco Research and Policy Studies, Truth Initiative, Washington, DC 20001, USA. david.b.abrams@nyu.edu.
Blair ColemanOffice of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA. Blair.Coleman@fda.hhs.gov.
Liane M SchnellerDepartment of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Liane.Schneller@RoswellPark.org.
Elizabeth Y LambertNational Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA. elambert@nida.nih.gov.
Jennifer L PearsonThe Schroeder Institute for Tobacco Research and Policy Studies, Truth Initiative, Washington, DC 20001, USA. jennipearson@unr.edu.ORCID 0000-0002-1400-5932
Maansi Bansal-TraversDepartment of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Maansi.Travers@RoswellPark.org.
Iilun MurphyOffice of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA. Iilun.Murphy@fda.hhs.gov.
Yu-Ching ChengOffice of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA. Yu-Ching.Cheng@fda.hhs.gov.
Elisabeth A DonaldsonOffice of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA. Elisabeth.Sherman@fda.hhs.gov.
Shari P FeirmanOffice of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA. Shari.Feirman@fda.hhs.gov.
Shannon GravelyDepartment of Psychology, University of Waterloo, Waterloo, ON N2L 3G1, Canada. shannon.gravely@uwaterloo.ca.
Tara Elton-MarshallInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, London, ON M5T 1R8, Canada. Tara.EltonMarshall@camh.ca.
Dennis R TrinidadDepartment of Family Medicine and Public Health, University of California, La Jolla, CA 92093, USA. dtrinidad@ucsd.edu.
Daniel A GundersenDepartment of Family Medicine and Community Health, Robert Wood Johnson Medical School, Rutgers, Somerset, NJ 08873, USA. DanielA_Gundersen@dfci.harvard.edu.
Raymond S NiauraThe Schroeder Institute for Tobacco Research and Policy Studies, Truth Initiative, Washington, DC 20001, USA. niaura@nyu.edu.
K Michael CummingsDepartment of Psychiatry & and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29425, USA. cummingk@musc.edu.
Wilson M ComptonNational Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA. wcompton@nida.nih.gov.
Andrew J HylandDepartment of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Andrew.Hyland@RoswellPark.org.

Funding

Intramural NIH HHS Z99 MD999999NIDA NIH HHS HHSN271201100027C
6 · The paper itself

Abstract

In 2013⁻2014, nearly 28% of adults in the United States (U.S.) were current tobacco users with cigarettes the most common product used and with nearly 40% of tobacco users using two or more tobacco products. We describe overall change in prevalence of tobacco product use and within-person transitions in tobacco product use in the U.S. between 2013⁻2014 and 2014⁻2015 for young adults (18⁻24 years) and older adults (25+ years). Data from Wave 1 (W1, 2013⁻2014) and Wave 2 (W2, 2014⁻2015) of the Population Assessment of Tobacco and Health (PATH) Study were analyzed (

Indexed as

AdultAgedElectronic Nicotine Delivery SystemsHumansMiddle AgedPrevalenceTobacco ProductsTobacco, SmokelessTobacco UseUnited StatesYoung Adultcigarettescigarselectronic nicotine delivery systems (ENDS)epidemiologyhookahlongitudinalpopulationsmokeless tobaccotobaccotransition

Identifiers

PMID30423998
PMCPMC6265905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.